# Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD

> **NCT05962645** · PHASE1 · COMPLETED · sponsor: **Altesa Biosciences, Inc.** · enrollment: 21 (actual)

## Conditions studied

- COPD
- Respiratory Disease
- Lower Respiratory Disease
- Pulmonary Disease
- Healthy

## Interventions

- **DRUG:** Vapendavir

## Key facts

- **NCT ID:** NCT05962645
- **Lead sponsor:** Altesa Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-19
- **Primary completion:** 2023-12-12
- **Final completion:** 2024-05-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05962645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05962645, "Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05962645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*